By SPC News Staff
The FDA granted a new indication for intravenous and subcutaneous belimumab (Benlysta, GlaxoSmithKline) for adults with active lupus nephritis (LN) who are receiving standard therapy.
Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE)—the most common form of lupus—that can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.
The FDA approval is based on the positive results of the